Susquehanna International Group
CRVS icon

Susquehanna International Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Susquehanna International Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.95M Buy
543,400
+199,300
+58% +$3.18M ﹤0.01% 3471
2025
Q4 		$2.65M Buy
344,100
+194,200
+130% +$1.53M ﹤0.01% 5101
2025
Q3 		$1.1M Buy
149,900
+107,300
+252% +$549K ﹤0.01% 7108
2025
Q2 		$170K Sell
42,600
-83,300
-66% -$303K ﹤0.01% 11370
2025
Q1 		$400K Sell
125,900
-33,300
-21% -$157K ﹤0.01% 9394
2024
Q4 		$852K Buy
159,200
+121,600
+323% +$908K ﹤0.01% 7371
2024
Q3 		$199K Buy
37,600
+22,700
+152% +$81.5K ﹤0.01% 10478
2024
Q2 		$27.1K Sell
14,900
-100
-0.7% -$186 ﹤0.01% 11589
2024
Q1 		$26.7K Buy
15,000
+1,600
+12% +$3.34K ﹤0.01% 11752
2023
Q4 		$23.6K Sell
13,400
-3,400
-20% -$4.97K ﹤0.01% 11939
2023
Q3 		$24.5K Buy
+16,800
New +$35.5K ﹤0.01% 11548
2022
Q3 		– Sell
-11,100
Closed -$11K – 13285
2022
Q2 		$11K Sell
11,100
-14,400
-56% -$17.7K ﹤0.01% 12491
2022
Q1 		$42K Sell
25,500
-38,800
-60% -$71K ﹤0.01% 12381
2021
Q4 		$155K Sell
64,300
-189,000
-75% -$733K ﹤0.01% 11755
2021
Q3 		$1.23M Buy
253,300
+238,200
+1,577% +$705K ﹤0.01% 7022
2021
Q2 		$40K Buy
+15,100
New +$41.6K ﹤0.01% 12340
2021
Q1 		– Sell
-62,900
Closed -$224K – 12307
2020
Q4 		$224K Buy
62,900
+14,300
+29% +$57.6K ﹤0.01% 9843
2020
Q3 		$195K Buy
+48,600
New +$194K ﹤0.01% 9471

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Susquehanna International Group's CRVS Position: Q1 2026 in Review

Susquehanna International Group reduced its Corvus Pharmaceuticals (CRVS) stake by 37% in Q1 2026, selling an estimated $369K and leaving 38,636 shares worth $565K. The position accounts for ﹤0.01% of the portfolio, ranked #9352.

Susquehanna International Group first reported a position in CRVS in Q4 2019 and has held it in 20 quarters since. The position peaked at $5.43M in Q4 2024. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Susquehanna International Group held 38,636 shares of Corvus Pharmaceuticals worth $565K as of Q1 2026.
  • Susquehanna International Group sold 23,118 Corvus Pharmaceuticals shares in Q1 2026, an estimated $369K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9352 holding.
  • Susquehanna International Group first reported a position in Corvus Pharmaceuticals in Q4 2019 and has held it in 20 quarters since.
  • Susquehanna International Group's Corvus Pharmaceuticals position peaked at $5.43M in Q4 2024.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.